The above results indicated that MLN8237 inhibited CD8+ T cell infiltration in tumor tissues, and anti-PD-L1 antibody could reverse the decrease of CD8+ T cell infiltration in tumor tissues induced by MLN8237 therapy. The gene discussed is CD8A; the disease is neoplasm.